BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bae J, Parayath N, Ma W, Amiji M, Munshi N, Anderson KC. BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia 2020;34:210-23. [PMID: 31427721 DOI: 10.1038/s41375-019-0540-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang X, He L, Huang X, Zhang S, Cao W, Che F, Zhu Y, Dai J. Recent Progress of Exosomes in Multiple Myeloma: Pathogenesis, Diagnosis, Prognosis and Therapeutic Strategies. Cancers (Basel) 2021;13:1635. [PMID: 33915822 DOI: 10.3390/cancers13071635] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Muluh TA, Chen Z, Li Y, Xiong K, Jin J, Fu S, Wu J. Enhancing Cancer Immunotherapy Treatment Goals by Using Nanoparticle Delivery System. Int J Nanomedicine 2021;16:2389-404. [PMID: 33790556 DOI: 10.2147/IJN.S295300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhong W, Zhang X, Zhao M, Wu J, Lin D. Advancements in nanotechnology for the diagnosis and treatment of multiple myeloma. Biomater Sci 2020;8:4692-711. [PMID: 32779645 DOI: 10.1039/d0bm00772b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Nijen Twilhaar MK, Czentner L, van Nostrum CF, Storm G, den Haan JMM. Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines. Pharmaceutics 2021;13:954. [PMID: 34202919 DOI: 10.3390/pharmaceutics13070954] [Reference Citation Analysis]
5 Tornesello AL, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L. Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines. Cancers (Basel) 2020;12:E1049. [PMID: 32340356 DOI: 10.3390/cancers12041049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
6 Allegra A, Gioacchino MD, Tonacci A, Petrarca C, Gangemi S. Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective. Nanomaterials (Basel) 2021;11:2792. [PMID: 34835555 DOI: 10.3390/nano11112792] [Reference Citation Analysis]
7 Podar K, Leleu X. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. Cancers (Basel) 2021;13:5154. [PMID: 34680303 DOI: 10.3390/cancers13205154] [Reference Citation Analysis]
8 Bilich T, Nelde A, Bauer J, Walz S, Roerden M, Salih HR, Weisel K, Besemer B, Marcu A, Lübke M, Schuhmacher J, Neidert MC, Rammensee HG, Stevanović S, Walz JS. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. Blood Cancer J 2020;10:24. [PMID: 32111817 DOI: 10.1038/s41408-020-0288-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
9 Wang J, Yang J, Kopeček J. Nanomedicines in B cell-targeting therapies. Acta Biomater 2021:S1742-7061(21)00692-9. [PMID: 34687954 DOI: 10.1016/j.actbio.2021.10.024] [Reference Citation Analysis]
10 Gao Y, Zhao Q, Xiao M, Huang X, Wu X. A versatile photothermal vaccine based on acid-responsive glyco-nanoplatform for synergistic therapy of cancer. Biomaterials 2021;273:120792. [PMID: 33872856 DOI: 10.1016/j.biomaterials.2021.120792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li F, Xu X, Liang Y, Li Y, Wang M, Zhao F, Wang X, Sun Y, Chen W. Nuclear-targeted nanocarriers based on pH-sensitive amphiphiles for enhanced GNA002 delivery and chemotherapy. Nanoscale 2021;13:4774-84. [PMID: 33576757 DOI: 10.1039/d0nr07239g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]